Archived: Re-purposing Existing Drugs to Treat COVID-19 | Benefits vs. Risks

Date: 19 May 2020

In just a few short months, the novel coronavirus SARS-CoV-2, which causes the disease COVID-19,  has become a global health pandemic, resulting in unprecedented hospitalizations and deaths of patients with severe symptoms.  The urgency to find effective therapies is an important focus of thousands of researchers.  Perhaps the most expedient approach to meeting this need explores the “re-purposing” of existing drugs which may mitigate symptoms or directly treat the infection.  Thus, a number of drugs, originally marketed for other indications, have (and continue to be) investigated in the hopes of helping COVID-19 patients in desperate need.

This webinar reviewed many of the re-purposed agents (such as chloroquine, hydroxychloroquine–with and without azithromycin, remdesivir, others) along with the preclinical and clinical data associated with their impact on the virus and COVID-19 patients.  Importantly, this data was viewed in the context of a risk-to-benefit assessment, based on known risks associated with the drugs and potential new risks in a vulnerable patient population.  The presentation also revealed some of the blind spots associated with anecdotal clinical data from small clinical trials, along with how definitive clinical trials differ in their use of methodologies such as double-blinding, randomization and control groups.

Finally, a brief review of some of the approaches being used to discover new therapies designed specifically for SARS-CoV-2 was discussed.

This FREE webinar was presented by Dr Bryan Norman. Bryan is the tutor on the 1.5 day course: Medicinal Chemistry Strategies to Mitigate Preclinical Safety Risks in Drug Discovery and the following VIRTUAL TRAINING WORKSHOPS:

DRUG DISCOVERY SAFETY ASSESSMENT FOR CHEMISTS
May 26th & 27th
This is a VIRTUAL short course that will look at the unexpected safety risks that arise during nearly every drug discovery effort.
Session 1 – May 26, 3.00 – 4.30 pm (BST)
Session 2 – May 27, 3.00 – 4.30 pm (BST) 

DRUG METABOLISM AND PHARMACOKINETICS (DMPK) IN DRUG DISCOVERY
June 2nd & 3rd
This is a VIRTUAL short course that will look at optimizing a drug metabolism profile as one of the most important actions in drug discovery.
Session 1 – June 2, 3.00 – 4.30 pm (BST)
Session 2 – June 3, 3.00 – 4.30 pm (BST)

COMMON OFF-TARGET AND ON-TARGET SAFETY RISKS IN DRUG DISCOVERY
June 9th & 10th
This is a VIRTUAL short course that will look at drug safety risks that emerge due to the engagement of unintended targets, along with engaging intended targets in unintended tissues
Session 1 – June 9, 3.00 – 4.30 pm (BST)
Session 2 – June 10, 3.00 – 4.30 pm (BST)

Each of these 2-day courses are priced at £95 per course to attend.

 

Gold Sponsor

×

Webinar Slides

We'll send you an email with the slides attached.